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In February 2019, the U.S. Department of Health and 
Human Services proposed a strategic initiative to end the 
human immunodeficiency (HIV) epidemic in the United 
States by reducing new HIV infections by 90% during 
2020–2030* (1). Phase 1 of the Ending the HIV Epidemic 
initiative focuses on Washington, DC; San Juan, Puerto Rico; 
and 48 counties where the majority of new diagnoses of HIV 
infection in 2016 and 2017 were concentrated and on seven 
states with a disproportionate occurrence of HIV in rural areas 
relative to other states.† One of the four pillars in the initiative 
is protecting persons at risk for HIV infection using proven, 
comprehensive prevention approaches and treatments, such as 
HIV preexposure prophylaxis (PrEP), which is the use of anti-
retroviral medications that have proven effective at preventing 
infection among persons at risk for acquiring HIV. In 2014, 
CDC released clinical PrEP guidelines to health care providers 
(2) and intensified efforts to raise awareness and increase the 
use of PrEP among persons at risk for infection, including gay, 
bisexual, and other men who have sex with men (MSM), a 
group that accounted for an estimated 68% of new HIV infec-
tions in 2016 (3). Data from CDC’s National HIV Behavioral 
Surveillance (NHBS) were collected in 20 U.S. urban areas in 
2014 and 2017, covering 26 of the geographic areas included 
in Phase I of the Ending the HIV Epidemic initiative, and 
were compared to assess changes in PrEP awareness and use 
among MSM. From 2014 to 2017, PrEP awareness increased 
by 50% overall, with >80% of MSM in 17 of the 20 urban 
areas reporting PrEP awareness in 2017. Among MSM with 
likely indications for PrEP (e.g., sexual risk behaviors or recent 
bacterial sexually transmitted infection [STI]), use of PrEP 
* https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/
overview?s_cid=ht_endinghivinternet0002.
† https://aidsvu.org/ending-the-epidemic/.
increased by approximately 500% from 6% to 35%, with 
significant increases observed in all urban areas and in almost 
all demographic subgroups. Despite this progress, PrEP use 
among MSM, especially among black and Hispanic MSM, 
remains low. Continued efforts to improve coverage are needed 
to reach the goal of 90% reduction in HIV incidence by 2030. 
In addition to developing new ways of connecting black and 
Hispanic MSM to health care providers through demonstration 
projects, CDC has developed resources and tools such as the 
Prescribe HIV Prevention program to enable health care pro-
viders to integrate PrEP into their clinical care.§ By routinely 
testing their patients for HIV, assessing HIV-negative patients 
for risk behaviors, and prescribing PrEP as needed, health care 
providers can play a critical role in this effort.
NHBS staff members in 20 urban areas collected cross-sectional 
behavioral survey data and conducted HIV testing among MSM 
§ https://www.cdc.gov/actagainstaids/campaigns/prescribe-hiv-prevention/index.html.
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at recruitment events using venue-based sampling¶ (4). Eligible 
participants** completed a standardized questionnaire admin-
istered in person by trained interviewers. All participants were 
offered anonymous HIV testing and incentives for the interview 
and HIV test.†† Analysis was limited to eligible participants at 
risk for HIV infection who were likely to meet clinical indications 
for PrEP§§ (2). Specifically, the analysis was limited to MSM who 
had a negative NHBS HIV test result, did not report a previous 
 ¶ The number of U.S. urban areas collecting data differed in 2014 and 2017. 
The following 20 urban areas collected data both years: Atlanta, Georgia; 
Baltimore, Maryland; Boston, Massachusetts; Chicago, Illinois; Dallas, Texas; 
Denver, Colorado; Detroit, Michigan; Houston, Texas; Los Angeles, 
California; Miami, Florida; Nassau and Suffolk counties, New York; New 
Orleans, Louisiana; New York City, New York; Newark, New Jersey; 
Philadelphia, Pennsylvania; San Diego, California; San Francisco, California; 
San Juan, Puerto Rico; Seattle, Washington; and Washington, DC. The 
following three urban areas that collected data in 2017 were not included in 
this analysis: Memphis, Tennessee; Norfolk, Virginia; and Portland, Oregon.
 ** Men who were born male and identified as male, reported having ever had 
oral or anal sex with another man, resided in the interview city, were 
aged ≥18 years, and could complete the interview in English or Spanish.
 †† The incentive format (cash or gift card) and amount varied by city according 
to formative assessment and local policy. A typical format included $25 for 
completing the interview and $25 for providing a specimen for HIV testing.
 §§ NHBS data do not correspond directly with the criteria for PrEP indication 
in the clinical guidelines. The guidelines recommend that men use PrEP if 
they are without acute or established HIV infection, have had sex with a 
nonmonogamous male partner who has not recently tested HIV-negative, 
and have had at least one of the following: any anal sex without a condom in 
the past 6 months or a bacterial STI (i.e., syphilis, gonorrhea, or chlamydia) 
diagnosed or reported in the past 6 months. NHBS data flag persons who are 
likely indicated for PrEP use because of behavior from a longer period 
(12 months versus 6 months) and use multiple sex partners as a proxy for a 
nonmonogamous partner.
HIV-positive test result, had either one male sex partner who 
was HIV-positive or two or more male sex partners in the past 
12 months, and reported either condomless anal sex or a bacterial 
STI (i.e., syphilis, gonorrhea, or chlamydia) in the past 12 months. 
PrEP awareness and use were measured differently in 2014 and 
in 2017. In 2014, participants were asked whether they had “ever 
heard of people who do not have HIV taking anti-HIV medicines, 
to keep from getting HIV” and whether, in the past 12 months, 
they had “taken anti-HIV medicines before sex because you 
thought it would keep you from getting HIV.” In 2017, par-
ticipants were informed that PrEP is an antiretroviral medicine 
taken for months or years by a person who is HIV-negative to 
reduce the risk for getting HIV and then asked whether they had 
ever heard of PrEP and whether, in the past 12 months they had 
taken PrEP to reduce the risk of getting HIV. Log-linked Poisson 
regression models with generalized estimating equations clustered 
on recruitment event were stratified by subgroup to estimate 
prevalence ratios and 95% confidence intervals (CIs) for PrEP 
awareness and use by year. Stratified models for each subgroup 
were adjusted for income, health insurance, and region. Analyses 
were conducted using SAS software (version 9.4; SAS Institute).
In 2014 and 2017, 18,610 sexually active MSM were interviewed 
(9,640 in 2014; 8,970 in 2017) in the 20 urban areas. Of those, 
this analysis is limited to 7,873 MSM (42%) who had a negative 
HIV test result but were at risk for HIV infection and likely met the 
clinical indications for PrEP (3,821 [40%] in 2014; 4,052 [45%] 
in 2017). From 2014 to 2017, awareness of PrEP among these 
MSM increased overall from 60% to 90% (adjusted prevalence 
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ratio [aPR] = 1.45; 95% CI = 1.41–1.50) and increased in all urban 
areas and subgroups (Table 1). In 2017, >80% of MSM in 17 of 
20 urban areas and in most demographic subgroups were aware 
of PrEP. From 2014 to 2017, use of PrEP among MSM increased 
overall from 6% to 35% (aPR = 5.66; 95% CI = 4.85–6.61) and 
increased in all urban areas and in almost all demographic subgroups 
(Table 2). Substantial increases in PrEP use occurred among black, 
Hispanic, and young (aged 18–29 years) MSM from 2014 to 2017. 
In 2017, the differences in PrEP use between Hispanic (30%) 
and white (42%) MSM (aPR = 0.91; 95% CI = 0.78–1.06) 
and between young (32%) and older (38%) MSM (aPR = 0.97; 
95% CI = 0.89–1.05) were no longer significant after controlling 
for income, health insurance, and region. However, the difference 
in reported PrEP use between black (26%) and white (42%) 
MSM remained significant after controlling for these three fac-
tors (aPR = 0.78; 95% CI = 0.66–0.92). During 2017, PrEP use 
increased with education and income, and 39% of the MSM who 
saw a health care provider in the past 12 months reported PrEP use.
TABLE 1. Number and percentage of men who have sex with men who are at risk for human immunodeficiency virus (HIV) infection* and 
reported awareness of HIV preexposure prophylaxis, by demographic characteristics — National HIV Behavioral Surveillance System, United 
States, 2014 and 2017
Characteristic
2014 2017
Adjusted prevalence  
ratio† (95% CI)No. (%) Total No. (%) Total
Overall 2,286 (59.8) 3,821 3,664 (90.4) 4,052 1.45 (1.41–1.50)
Age group (yrs)
18–29 1,115 (57.5) 1,939 1,717 (91.2) 1,882 1.52 (1.45–1.59)
≥30 1,171 (62.2) 1,882 1,947 (89.7) 2,170 1.40 (1.34–1.46)
Racial/Ethnic group
Black 376 (47.1) 798 729 (86.2) 846 1.76 (1.62–1.92)
Hispanic/Latino 529 (48.9) 1,081 1,032 (86.6) 1,191 1.66 (1.55–1.77)
White 1,152 (71.7) 1,607 1,555 (94.5) 1,645 1.30 (1.25–1.35)
Other§ 216 (68.4) 316 322 (93.6) 344 1.36 (1.25–1.48)
Sexual identity
Heterosexual 12 (38.7) 31 12 (60.0) 20 1.55 (0.87–2.76)
Homosexual or gay 2,038 (63.3) 3,222 3,126 (92.2) 3,389 1.41 (1.36–1.45)
Bisexual 227 (40.9) 555 513 (81.4) 630 1.90 (1.71–2.12)
Education
High school degree or less 353 (38.8) 910 604 (80.5) 750 1.98 (1.79–2.17)
Some college or vocational school 695 (56.2) 1,237 1,184 (90.5) 1,309 1.56 (1.48–1.65)
College degree or graduate studies 1,237 (73.9) 1,673 1,875 (94.1) 1,992 1.26 (1.22–1.30)
Household income
$0–$24,999 593 (45.5) 1,303 838 (82.2) 1,019 1.73 (1.61–1.85)
$25,000–$49,999 622 (61.5) 1,012 1,000 (91.0) 1,099 1.46 (1.38–1.55)
$50,000–$74,999 428 (66.9) 640 755 (93.8) 805 1.39 (1.31–1.48)
≥$75,000 620 (75.7) 819 1,058 (95.3) 1,110 1.26 (1.20–1.31)
Currently have health insurance
No 463 (51.1) 906 621 (85.5) 726 1.59 (1.48–1.72)
Yes 1,818 (62.6) 2,906 3,039 (91.6) 3,319 1.42 (1.37–1.47)
Visited a health care provider within the past 12 months
No 332 (47.1) 705 409 (78.8) 519 1.60 (1.46–1.76)
Yes 1,953 (62.7) 3,114 3,254 (92.1) 3,532 1.42 (1.37–1.47)
Usual source of health care
No usual place for health care 386 (46.3) 834 570 (83.3) 684 1.72 (1.58–1.87)
Clinic or health care center 599 (61.8) 970 1,053 (91.3) 1,153 1.43 (1.35–1.51)
Doctor’s office or HMO 1,218 (64.8) 1,881 1,888 (92.6) 2,039 1.39 (1.34–1.44)
Other place for health care 57 (62.0) 92 115 (87.8) 131 1.42 (1.19–1.69)
See table footnotes on next page.
Discussion
From 2014 to 2017, PrEP awareness among MSM in this 
analysis increased by 50%. More importantly, in 2017, >80% 
of MSM in all racial and ethnic groups and in 17 of the 20 
urban areas were aware of PrEP. This finding is encouraging 
and suggests that efforts designed to increase PrEP awareness 
among populations at risk for HIV infection are having a 
positive impact. These efforts have included media and social 
marketing campaigns (e.g., Act Against AIDS¶¶). In addi-
tion, national HIV prevention goals were updated in 2015 to 
expand efforts to prevent HIV infection using a combination of 
effective, evidence-based approaches among populations with 
the highest prevalences of HIV infection, including among 
black and Hispanic MSM (5). Thus, continued increases of 
awareness among MSM, especially among black and Hispanic 
MSM, are expected.
 ¶¶ https://www.cdc.gov/actagainstaids/index.html.
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TABLE 1. (Continued) Number and percentage of men who have sex with men who are at risk for human immunodeficiency virus (HIV) infection* 
and reported awareness of HIV preexposure prophylaxis, by demographic characteristics — National HIV Behavioral Surveillance System, 
United States, 2014 and 2017
Characteristic
2014 2017
Adjusted prevalence  
ratio† (95% CI)No. (%) Total No. (%) Total
Participated in a behavioral Intervention within the past 12 months
No 1,627 (57.2) 2,842 2,486 (88.9) 2,797 1.49 (1.43–1.55)
Yes 659 (67.3) 979 1,176 (93.9) 1,253 1.33 (1.27–1.40)
Tested for HIV within the past 12 months
No 348 (41.5) 838 452 (75.1) 602 1.73 (1.57–1.91)
Yes 1,935 (65.0) 2,976 3,207 (93.1) 3,444 1.39 (1.35–1.43)
Region¶
Midwest 216 (61.2) 353 289 (80.7) 358 1.29 (1.13–1.46)
Northeast 471 (59.4) 793 718 (90.4) 794 1.51 (1.40–1.62)
South 755 (55.9) 1,350 1,239 (89.6) 1,383 1.53 (1.44–1.62)
U.S. territories 63 (27.6) 228 82 (66.7) 123 2.25 (1.75–2.89)
West 781 (71.2) 1,097 1,336 (95.8) 1,394 1.34 (1.28–1.41)
Urban area
Atlanta, GA 119 (62.0) 192 184 (92.5) 199 1.43 (1.25–1.64)
Baltimore, MD 87 (55.4) 157 89 (82.4) 108 1.52 (1.28–1.81)
Boston, MA 106 (73.1) 145 203 (96.7) 210 1.33 (1.18–1.49)
Chicago, IL 162 (82.2) 197 186 (94.4) 197 1.13 (1.05–1.22)
Dallas, TX 59 (33.1) 178 224 (89.2) 251 2.28 (1.76–2.97)
Denver, CO 122 (58.1) 210 270 (93.8) 288 1.61 (1.41–1.83)
Detroit, MI 54 (34.6) 156 103 (64.0) 161 1.80 (1.41–2.31)
Houston, TX 93 (49.7) 187 212 (86.5) 245 1.67 (1.38–2.01)
Los Angeles, CA 177 (68.3) 259 287 (97.3) 295 1.44 (1.31–1.57)
Miami, FL 98 (46.4) 211 134 (78.8) 170 1.67 (1.40–2.00)
Nassau and Suffolk counties, NY 73 (45.9) 159 68 (84.0) 81 1.83 (1.50–2.23)
New Orleans, LA 100 (55.2) 181 156 (94.5) 165 1.66 (1.42–1.94)
New York City, NY 125 (80.1) 156 236 (95.2) 248 1.17 (1.08–1.27)
Newark, NJ 22 (25.0) 88 48 (88.9) 54 3.73 (2.69–5.18)
Philadelphia, PA 145 (59.2) 245 163 (81.1) 201 1.36 (1.18–1.57)
San Diego, CA 139 (63.8) 218 277 (94.2) 294 1.47 (1.30–1.67)
San Francisco, CA 158 (90.8) 174 261 (97.4) 268 1.05 (1.00–1.12)
San Juan, PR 63 (27.6) 228 82 (66.7) 123 2.25 (1.75–2.89)
Seattle, WA 185 (78.4) 236 241 (96.8) 249 1.24 (1.16–1.33)
Washington, DC 199 (81.6) 244 240 (98.0) 245 1.19 (1.12–1.27)
Abbreviations: CI = confidence interval; HMO = health maintenance organization.
* Men who were at risk for HIV infection and likely to meet clinical indications for HIV preexposure prophylaxis. This was defined as men who had a negative HIV test 
result at the time of the interview, did not report a previous HIV-positive test result, had either one male sex partner who was HIV-positive or multiple male sex 
partners in the past 12 months, and reported either condomless anal sex or a sexually transmitted bacterial infection in the past 12 months.
† Models adjusted for income, health insurance, and region.
§ Includes American Indian, Alaskan Native, Asian, Native Hawaiian, Pacific Islander, or multiple races.
¶ Midwest region includes Chicago, IL and Detroit, MI. Northeast region includes Boston, MA; Nassau and Suffolk counties, NY; New York City, NY; Newark, NJ; and 
Philadelphia, PA. South region includes Atlanta, GA; Baltimore, MD; Dallas, TX; Houston, TX; Miami, FL; New Orleans, LA; and Washington, DC. U.S. territories region 
includes San Juan, PR. West region includes Denver, CO; Los Angeles, CA; San Diego, CA; San Francisco, CA; and Seattle, WA.
Although PrEP use by MSM in this analysis increased approxi-
mately 500% from 2014 to 2017, only approximately one in 
three men at risk for HIV infection reported using PrEP. Models 
examining the impact of PrEP use on incidence predict that the 
use of PrEP by 30%–40% of MSM with PrEP indications in a 
community could result in approximately one third of new HIV 
infections being averted over a 10-year period, with a greater pre-
dicted impact if coverage is increased (6). The reported increase in 
PrEP use among MSM is promising, but higher coverage is needed 
to reduce incidence of new infections by 90% within the 10 years 
of the Ending the HIV Epidemic initiative.
The overall impact and efficiency of PrEP at averting new infec-
tions is greater in communities with a high prevalence of HIV (7,8). 
Therefore, efforts focused on increasing PrEP use among black and 
Hispanic MSM, who have a higher prevalence of HIV infection 
(3), might substantially reduce the incidence of HIV infections. The 
large percentage increases in PrEP use among black and Hispanic 
MSM in this analysis are promising, but PrEP use in these groups 
remains low; continued efforts will be needed to meet the goals of 
the Ending the HIV Epidemic initiative. Because of the structural 
barriers associated with race that influence access to quality health 
care (9), demonstration projects for the Targeted Highly-Effective 
Interventions to Reverse the HIV Epidemic (THRIVE) program*** 
are underway in seven U.S. cities. These projects establish community 
 *** https://www.cdc.gov/hiv/research/thrive/about.html.
Morbidity and Mortality Weekly Report
MMWR / July 12, 2019 / Vol. 68 / No. 27 601US Department of Health and Human Services/Centers for Disease Control and Prevention
TABLE 2. Number and percentage of men who have sex with men who are at risk for human immunodeficiency virus (HIV) infection* and 
reported using HIV preexposure prophylaxis, by demographic characteristics — National HIV Behavioral Surveillance System, United States, 
2014 and 2017
Characteristic
2014 2017
Adjusted prevalence  
ratio† (95% CI)No. (%) Total No. (%) Total
Overall 216 (5.7) 3,821 1,425 (35.1) 4,052 5.66 (4.85–6.61)
Age group (yrs)
18–29 90 (4.6) 1,939 608 (32.3) 1,882 6.36 (5.05–8.02)
≥30 126 (6.7) 1,882 817 (37.6) 2,170 5.21 (4.30–6.32)
Racial/Ethnic group
Black 30 (3.8) 798 222 (26.2) 846 6.44 (4.36–9.51)
Hispanic/Latino 41 (3.8) 1,081 357 (30.0) 1,191 6.92 (5.08–9.44)
White 133 (8.3) 1,607 697 (42.4) 1,645 4.83 (3.96–5.88)
Other§ 12 (3.8) 316 137 (39.8) 344 9.53 (5.36–16.96)
Sexual identity
Heterosexual 2 (6.5) 31 3 (15.0) 20 2.33 (0.42–12.78)
Homosexual or gay 196 (6.1) 3,222 1,273 (37.6) 3,389 5.65 (4.81–6.63)
Bisexual 18 (3.2) 555 144 (22.9) 630 6.43 (3.96–10.45)
Education
High school degree or less 19 (2.1) 910 192 (25.6) 750 10.76 (6.69–17.33)
Some college or vocational school 55 (4.4) 1,237 390 (29.8) 1,309 6.77 (5.14–8.92)
College degree or graduate studies 142 (8.5) 1,673 842 (42.3) 1,992 4.80 (3.99–5.77)
Household income
$0–$24,999 48 (3.7) 1,303 264 (25.9) 1,019 6.20 (4.51–8.52)
$25,000–$49,999 45 (4.4) 1,012 346 (31.5) 1,099 6.82 (5.00–9.32)
$50,000–$74,999 34 (5.3) 640 294 (36.5) 805 6.89 (4.89–9.71)
≥$75,000 88 (10.7) 819 521 (46.9) 1,110 4.29 (3.43–5.37)
Currently have health insurance
No 23 (2.5) 906 134 (18.5) 726 6.63 (4.35–10.10)
Yes 192 (6.6) 2,906 1,290 (38.9) 3,319 5.53 (4.70–6.51)
Visited a health care provider within the past 12 months
No 5 (0.7) 705 37 (7.1) 519 9.81 (3.87–24.85)
Yes 211 (6.8) 3,114 1,388 (39.3) 3,532 5.38 (4.60–6.28)
Usual source of health care
No usual place for health care 18 (2.2) 834 111 (16.2) 684 7.08 (4.36–11.48)
Clinic or health care center 59 (6.1) 970 426 (37.0) 1,153 5.68 (4.36–7.38)
Doctor’s office or HMO 136 (7.2) 1,881 850 (41.7) 2,039 5.34 (4.41–6.46)
Other place for health care 2 (2.2) 92 30 (22.9) 131 9.69 (2.38–39.38)
See table footnotes on next page.
collaboratives that provide comprehensive HIV prevention and care 
services for black and Hispanic MSM. Lessons learned from these 
efforts might help further inform how best to increase PrEP use 
among these populations.
Some health care providers might be missing opportunities to 
provide PrEP to patients who would benefit from its use. MSM 
included in this analysis reported behaviors that put them at sub-
stantial risk for HIV infection, yet only 39% of those who saw a 
health care provider in the past 12 months reported using PrEP. 
CDC’s HIV PrEP clinical practice guideline offers comprehensive 
information to providers for prescribing and managing PrEP and 
recommends that health care providers take routine sexual histories 
of all their patients (2). However, some providers only take a sexual 
history if it is related to the patient’s complaint and ask nonspecific 
questions about sex (10). To increase PrEP use, health care provid-
ers might need training and resources to ensure they know how 
to assess their patients for indications for PrEP and are confident 
discussing PrEP medication. As part of CDC’s Act Against AIDS 
communication campaign, the Prescribe HIV Prevention program 
offers an online toolkit to help health care providers use PrEP to 
prevent new HIV infections among patients at high risk. This 
toolkit includes resources such as answers to frequently asked 
questions about PrEP medication and its related clinical care, 
campaign posters to help raise PrEP awareness, patient materials, 
a tool to aid health care providers in discussing sexual histories 
with their patients, and continuing medical education courses on 
PrEP. To fulfill their critical role in reducing new HIV infections 
in the United States, health care providers will need to routinely 
test patients for HIV, link those with HIV infection to care, and 
discuss HIV prevention options (e.g., condoms and PrEP) with 
those who are not infected.
The findings in this report are subject to at least six limitations. 
First, NHBS data do not correspond directly with the criteria for 
PrEP indication in the clinical guidelines. NHBS uses a 12-month 
period for assessing risk behaviors versus a 6-month period specified 
in the clinical guidelines. Second, this analysis used having two or 
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TABLE 2. (Continued) Number and percentage of men who have sex with men who are at risk for human immunodeficiency virus (HIV) infection* 
and reported using HIV preexposure prophylaxis, by demographic characteristics — National HIV Behavioral Surveillance System, United 
States, 2014 and 2017
Characteristic
2014 2017
Adjusted prevalence  
ratio† (95% CI)No. (%) Total No. (%) Total
Participated in a behavioral Intervention within the past 12 months
No 118 (4.2) 2,842 858 (30.7) 2,797 6.64 (5.38–8.19)
Yes 98 (10.0) 979 565 (45.1) 1,253 4.03 (3.31–4.90)
Tested for HIV within the past 12 months
No 3 (0.4) 838 19 (3.2) 602 8.33 (2.46–28.24)
Yes 213 (7.2) 2,976 1,406 (40.8) 3,444 5.26 (4.51–6.12)
Region¶
Midwest 27 (7.6) 353 117 (32.7) 358 3.91 (2.35–6.52)
Northeast 46 (5.8) 793 293 (36.9) 794 5.78 (4.21–7.95)
South 69 (5.1) 1,350 409 (29.6) 1,383 5.44 (4.18–7.08)
U.S. territories 2 (0.9) 228 7 (5.7) 123 5.08 (1.19–21.74)
West 72 (6.6) 1,097 599 (43.0) 1,394 6.36 (4.87–8.30)
Urban area
Atlanta, GA 12 (6.3) 192 56 (28.1) 199 4.29 (2.08–8.84)
Baltimore, MD 8 (5.1) 157 20 (18.5) 108 3.39 (1.53–7.55)
Boston, MA 11 (7.6) 145 105 (50.0) 210 6.33 (3.16–12.65)
Chicago, IL 23 (11.7) 197 93 (47.2) 197 3.79 (2.22–6.47)
Dallas, TX 4 (2.2) 178 63 (25.1) 251 11.12 (3.52–35.16)
Denver, CO 4 (1.9) 210 92 (31.9) 288 15.71 (5.97–41.30)
Detroit, MI 4 (2.6) 156 24 (14.9) 161 5.49 (2.05–14.66)
Houston, TX 9 (4.8) 187 60 (24.5) 245 4.66 (2.48–8.75)
Los Angeles, CA 11 (4.2) 259 109 (36.9) 295 9.13 (4.97–16.78)
Miami, FL 5 (2.4) 211 30 (17.6) 170 7.75 (3.26–18.41)
Nassau and Suffolk counties, NY 3 (1.9) 159 15 (18.5) 81 9.81 (3.03–31.79)
New Orleans, LA 5 (2.8) 181 65 (39.4) 165 12.99 (5.55–30.43)
New York City, NY 8 (5.1) 156 101 (40.7) 248 6.88 (3.61–13.10)
Newark, NJ 1 (1.1) 88 13 (24.1) 54 21.15 (2.97–150.41)
Philadelphia, PA 23 (9.4) 245 59 (29.4) 201 3.20 (2.03–5.04)
San Diego, CA 12 (5.5) 218 120 (40.8) 294 7.34 (4.11–13.13)
San Francisco, CA 26 (14.9) 174 164 (61.2) 268 3.93 (2.55–6.04)
San Juan, PR 2 (0.9) 228 7 (5.7) 123 5.08 (1.19–21.74)
Seattle, WA 19 (8.1) 236 114 (45.8) 249 5.44 (3.34–8.85)
Washington, DC 26 (10.7) 244 115 (46.9) 245 4.54 (3.08–6.70)
Abbreviations: CI = confidence interval; HMO = health maintenance organization.
* Men who were at risk for HIV infection and likely to meet clinical indications for HIV preexposure prophylaxis. This was defined as men who had a negative HIV test 
result at the time of the interview, did not report a previous HIV-positive test result, had either one male sex partner who was HIV-positive or multiple male sex 
partners in the past 12 months, and reported either condomless anal sex or a sexually transmitted bacterial infection in the past 12 months.
† Models adjusted for income, health insurance, and region.
§ Includes American Indian, Alaskan Native, Asian, Native Hawaiian, Pacific Islander, or multiple races.
¶ Midwest region includes Chicago, IL and Detroit, MI. Northeast region includes Boston, MA; Nassau and Suffolk counties, NY; New York City, NY; Newark, NJ; and 
Philadelphia, PA. South region includes Atlanta, GA; Baltimore, MD; Dallas, TX; Houston, TX; Miami, FL; New Orleans, LA; and Washington, DC. U.S. territories region 
includes San Juan, PR. West region includes Denver, CO; Los Angeles, CA; San Diego, CA; San Francisco, CA; and Seattle, WA.
more sex partners in the past year as a proxy for a nonmonogamous 
relationship, but these partnerships might not have overlapped in 
time. Thus, the analysis might include some men without indica-
tions for PrEP use. Their inclusion in the denominator might 
underestimate the percentage of men in NHBS using PrEP. Third, 
different questions were used to assess PrEP awareness and use in 
2014 and 2017. The measure of PrEP use in 2017 was more specific 
than that in 2014, so estimates of PrEP use increases are potentially 
underestimated. Fourth, NHBS is not nationally representative and 
might not be generalizable to all cities, nonurban areas, or MSM. 
Fifth, because data were not weighted to account for the complex 
sampling methods used to recruit MSM, estimates might be biased 
by over- or underestimating subgroups of the population. Finally, 
data on self-reported behaviors might be subject to recall and social 
desirability biases. Although the impact of recall bias on the analysis 
is unknown, social desirability bias might lead to overreporting PrEP 
awareness and use.
HIV PrEP awareness and use is increasing in the United States 
among MSM who are at risk for acquiring HIV, but higher cov-
erage is needed, especially among black and Hispanic MSM, to 
end the HIV epidemic in the United States by 2030. By routinely 
testing their patients for HIV, assessing HIV-negative patients 
for risk behaviors, and prescribing PrEP as needed, health care 
providers can play a critical role in this effort.
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Summary
What is already known about this topic?
Men who have sex with men (MSM) can reduce their risk for 
human immunodeficiency virus (HIV) infection by using 
preexposure prophylaxis (PrEP) consistently. Increasing PrEP use 
is a principal strategy of the Ending the HIV Epidemic initiative.
What is added by this report?
From 2014 to 2017, PrEP awareness among MSM in 20 urban 
areas increased from 60% to 90%, and PrEP use increased from 
6% to 35%. PrEP use increased in almost all demographic 
subgroups but remains lower among black and Hispanic MSM.
What are the implications for public health practice?
By routinely testing patients for HIV, assessing HIV-negative 
patients for risk behaviors, and prescribing PrEP as needed, health 
care providers can play a critical role in ending the HIV epidemic.
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